(Q37812846)

23 August 2017

title

HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury (English)

1 reference

23 August 2017

HIV Infection and the Liver: The Importance of HCV-HIV Coinfection and Drug-Induced Liver Injury (English)

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

4 September 2024

0 references

Shehzad N. Merwat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21111997

4 September 2024

John M. Vierling

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21111997

4 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21111997

4 September 2024

publication date

1 February 2011

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S1089326110000899?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

https://api.elsevier.com/content/article/PII:S1089326110000899?httpAccept=text/plain

4 September 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

4 September 2024

published in

Clinics in liver disease

1 reference

23 August 2017

volume

15

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

131-152

1 reference

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis C in the HIV-infected patient

4 September 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease

4 September 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

4 September 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment

4 September 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The challenge of hepatitis C in the HIV-infected person

4 September 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

4 September 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

4 September 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review

4 September 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

4 September 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London

4 September 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis

4 September 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study

4 September 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Acute hepatitis C and HIV coinfection

4 September 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The natural history of hepatitis C virus infection: host, viral, and environmental factors

4 September 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients

4 September 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

4 September 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

4 September 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis C is more severe in drug users with human immunodeficiency virus infection

4 September 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

4 September 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy

4 September 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis

4 September 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression

4 September 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes

4 September 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study

4 September 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

4 September 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

4 September 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

4 September 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

4 September 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

4 September 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

4 September 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients

4 September 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count

4 September 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults

4 September 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV.

4 September 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

4 September 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

4 September 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

4 September 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

4 September 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

A comparison of fibrosis progression in chronic liver diseases

4 September 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease

4 September 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study.

4 September 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Surveillance for hepatocellular carcinoma and early diagnosis

4 September 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse

4 September 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001.

4 September 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.

4 September 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Diagnosis, management, and treatment of hepatitis C: an update

4 September 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

4 September 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

4 September 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

4 September 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

4 September 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

4 September 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

4 September 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

4 September 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

4 September 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.

4 September 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

4 September 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

4 September 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection

4 September 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?

4 September 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

4 September 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

4 September 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients

4 September 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.

4 September 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases

4 September 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels

4 September 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase

4 September 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

4 September 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The liver biopsy in chronic hepatitis C: a view from the other side of the microscope

4 September 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection

4 September 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

4 September 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease

4 September 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

4 September 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

4 September 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

4 September 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

4 September 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

4 September 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

4 September 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?

4 September 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?

4 September 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

4 September 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases

4 September 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients

4 September 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life

4 September 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Approaching treatment for hepatitis C virus infection in substance users

4 September 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems

4 September 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

4 September 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy

4 September 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy

4 September 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

4 September 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Antiviral hepatitis and antiretroviral drug interactions

4 September 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

4 September 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

4 September 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases

4 September 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

4 September 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

4 September 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

4 September 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy

4 September 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

4 September 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

4 September 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

4 September 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century

4 September 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Management of end-stage liver disease in HIV-infected patients

4 September 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

4 September 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center

4 September 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.

4 September 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes

4 September 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.CLD.2010.09.012

4 September 2024

Identifiers

1 reference

release_4ekoe6dhjfexjdrhw4os3lqwsy

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4ekoe6dhjfexjdrhw4os3lqwsy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference